Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$2.85 CAD
Change Today -0.03 / -1.04%
Volume 258.0
As of 11:19 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

fennec pharmaceuticals inc (FRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/14 - C$3.99
52 Week Low
12/23/14 - C$2.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

fennec pharmaceuticals inc (FRX) Related Businessweek News

No Related Businessweek News Found

fennec pharmaceuticals inc (FRX) Details

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops therapeutic product for use in the treatment of cancer. Its lead product candidates include Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which is in two Phase III clinical trials for the prevention of cisplatin induced hearing loss or ototoxicity in children; and Eniluracil, an oral irreversible dihydropyrimidine dehydrogenase inhibitor, which has completed Phase II clinical trial in metastatic breast cancer. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

1 Employees
Last Reported Date: 03/31/15
Founded in 1996

fennec pharmaceuticals inc (FRX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $218.5K
Interim Chief Financial Officer
Total Annual Compensation: $144.7K
Compensation as of Fiscal Year 2014.

fennec pharmaceuticals inc (FRX) Key Developments

Fennec Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Fennec Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, loss from operations was $0.5 million against $0.9 million last year. Net loss was $0.2 million or $0.02 per basic and diluted share against $0.9 million or $0.08 per basic and diluted share last year. For the six months, loss from operations was $1.0 million against $1.5 million last year. Net income was $0.004 million against net loss of $3.9 million or $0.40 per basic and diluted share last year. Net cash used in operating activities was $0.9 million, as compared to $0.8 million during the same period in 2014. This increase is due to increased cash outlays incurred from ongoing STS Phase III trials, STS product development and general and administrative costs associated with the company's strategic initiatives designed to further develop new markets and partnering opportunities.

Fennec Pharmaceuticals Inc. Announces Presentation of Positive Interim Sodium Thiosulfate Phase III Safety Data at the 2015 ASCO Annual Meeting

Fennec Pharmaceuticals Inc. announced the presentation of positive interim results from a poster presented entitled, 'Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)'. The data was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. SIOPEL6 is a multi-centre open label randomized phase 3 study evaluating the efficacy of STS in reducing ototoxicity in patients receiving Cis monotherapy for SR-HB. The study is closed to recruitment and all protocol pre-specified IDMC safety reviews are now complete. From the beginning of 2007 to the end 2014, 45 sites from 11 countries enrolled 109 evaluable patients. Newly diagnosed patients with SR-HB were treated with weekly cycles of Cis every two weeks including 4 chemotherapy courses before primary tumor resection and 2 courses after surgery. Patients were randomized to Cis alone or Cis and STS. Cis of 80 mg/m2 was administered i.v. over 6 hrs. STS was administered i.v. exactly 6 hrs after stop of Cis over 15 minutes at 20 g/m2. Tumor response was assessed after 2 and 4 cycles pre-operative with serum AFP and liver imaging. In case of progression after 2 cycles, STS was stopped and doxorubicin 60 mg/m2 continuous infusion over 48 hrs added. The primary endpoint is centrally reviewed absolute hearing threshold, at the age of greater than or equal to 3.5 yrs, by pure tone audiometry. The trial has 80% power to detect a reduction in hearing loss defined as Brock grade = 1 from 60% of patients with Cis to 35% with Cis+STS. The efficacy results indicate that it is safe to treat SR-HB with six cycles of Cis monotherapy with the addition of the chemoprotectant STS. Efficacy results at the end treatment for the 109 evaluable patients (52 Cis, 57 Cis+STS) were complete response/partial response/progressive disease for Cis: 85%/6%/4% and for CIS+STS: 91%/7%/0%.

Fennec Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 11:30 AM

Fennec Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 11:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Rostislav Raykov, Chairman and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRX:CN C$2.85 CAD -0.03

FRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation FRX Industry Range
Price/Earnings 13.6x
Price/Sales -- Not Meaningful
Price/Book 20.7x
Price/Cash Flow 13.0x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FENNEC PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at